on September 21, 2006
Published online before print September 21, 2006, doi: 10.1161/01.STR.0000244767.39962.f7
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on March 7, 2006
From the Departments of Hematology (T.N.B., M.P.M.d.M., V.B., H.H.D.M.v.V., E.B.G.C., F.W.G.L.) and Neurology (M.P.J.v.G., D.W.J.D.), Erasmus University Medical Center, Rotterdam, The Netherlands. * To whom correspondence should be addressed. E-mail: t.bongers{at}erasmusmc.nl.
Background and Purpose--Elevated von Willebrand factor (vWF) concentrations are associated with an increased risk of ischemic heart disease. Several factors influence vWF antigen levels and activity, including blood group, genetic variability, acute-phase response, and proteolysis by A Disintegrin and Metalloprotease with ThromboSpondin motif (ADAMTS13), a determinant of proteolytic cleavage of vWF. We assessed how these factors affect the relation between vWF and the occurrence of stroke to understand the underlying mechanism. Methods--In a case-control study of 124 first-ever ischemic stroke patients and 125 age- and sex-matched controls, we studied vWF antigen (vWF:Ag), vWF ristocetin cofactor activity (vWF:RCo), ADAMTS13 activity, the -1793C/G polymorphism in the vWF gene, and C-reactive protein. Results--vWF antigen and activity levels were significantly higher in cases than in controls. The relative risk of ischemic stroke was highest in individuals in the upper quartile of vWF:Ag (odds ratio, 3.2; 95% CI, 1.4 to 7.5) and vWF:RCo (odds ratio, 2.1; 95% CI, 0.9 to 4.8) compared with individuals in the lowest quartiles. In individuals with ADAMTS13 in the lowest quartile, the relative risk of stroke was 1.7 (95% CI, 0.7 to 3.9) compared with the highest quartile. C-reactive protein, ADAMTS13, and genetic variation did not affect the association between vWF and the relative risk of stroke, whereas blood group did affect the association. Conclusions--vWF antigen and activity are associated with the occurrence of acute ischemic stroke. This relation is unaffected by the severity of the acute-phase response or by genetic variation or degradation.
Revised on May 22, 2006
Accepted on July 5, 2006
High von Willebrand Factor Levels Increase the Risk of First Ischemic Stroke. Influence of ADAMTS13, Inflammation, and Genetic Variability
Tamara N. Bongers MSc*;
Key words: ADAMTS13 • hemostasis • ischemic stroke • von Willebrand factor
This article has been cited by other articles:
 |
|
 |
|
  A. M. Kucharska-Newton, D. J. Couper, J. S. Pankow, R. J. Prineas, T. D. Rea, N. Sotoodehnia, A. Chakravarti, A. R. Folsom, D. S. Siscovick, and W. D. Rosamond Hemostasis, Inflammation, and Fatal and Nonfatal Coronary Heart Disease: Long-Term Follow-Up of the Atherosclerosis Risk in Communities (ARIC) Cohort Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2182 - 2190. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-Q. Zhao, A. K. Chauhan, M. Canault, I. S. Patten, J. J. Yang, M. Dockal, F. Scheiflinger, and D. D. Wagner von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke Blood, October 8, 2009; 114(15): 3329 - 3334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Tietjen, N. A. Herial, L. White, C. Utley, J. M. Kosmyna, and S. A. Khuder Migraine and Biomarkers of Endothelial Activation in Young Women Stroke, September 1, 2009; 40(9): 2977 - 2982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mayr, D. Grainger, U. Mayr, A. S. Leroyer, G. Leseche, A. Sidibe, O. Herbin, X. Yin, A. Gomes, B. Madhu, et al. Proteomics, Metabolomics, and Immunomics on Microparticles Derived From Human Atherosclerotic Plaques Circ Cardiovasc Genet, August 1, 2009; 2(4): 379 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kleinschnitz, S. F. De Meyer, T. Schwarz, M. Austinat, K. Vanhoorelbeke, B. Nieswandt, H. Deckmyn, and G. Stoll Deficiency of von Willebrand factor protects mice from ischemic stroke Blood, April 9, 2009; 113(15): 3600 - 3603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kajimoto, K. Miyauchi, T. Kasai, N. Yanagisawa, T. Yamamoto, K. Kikuchi, T. Nakatomi, H. Iwamura, H. Daida, and A. Amano Metabolic syndrome is an independent risk factor for stroke and acute renal failure after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 658 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Frankel, J. B. Meigs, J. M. Massaro, P. W.F. Wilson, C. J. O'Donnell, R. B. D'Agostino, and G. H. Tofler Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study Circulation, December 9, 2008; 118(24): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Stoll, C. Kleinschnitz, and B. Nieswandt Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment Blood, November 1, 2008; 112(9): 3555 - 3562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Chauhan, J. Kisucka, A. Brill, M. T. Walsh, F. Scheiflinger, and D. D. Wagner ADAMTS13: a new link between thrombosis and inflammation J. Exp. Med., September 1, 2008; 205(9): 2065 - 2074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kleinschnitz, M. Pozgajova, M. Pham, M. Bendszus, B. Nieswandt, and G. Stoll Targeting Platelets in Acute Experimental Stroke: Impact of Glycoprotein Ib, VI, and IIb/IIIa Blockade on Infarct Size, Functional Outcome, and Intracranial Bleeding Circulation, May 1, 2007; 115(17): 2323 - 2330. [Abstract] [Full Text] [PDF]
|
|